Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Pharmacoeconomics
Κύριοι συγγραφείς: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer International Publishing 2015
Θέματα:
Review Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://ncbi.nlm.nih.gov/pubmed/26314282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0318-3
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια